Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 8—August 2019

Evaluating Temperature Sensitivity of Vesicular Stomatitis Virus–Based Vaccines

Derek R. Stein, Patrycja Sroga, Bryce M. Warner, Yvon Deschambault, Guillaume Poliquin, and David SafronetzComments to Author 
Author affiliations: Public Health Agency of Canada, Winnipeg, Manitoba, Canada (D.R. Stein, Y. Deschambault, G. Poliquin, D. Safronetz); University of Manitoba, Winnipeg (P. Sroga, B.M. Warner, G. Poliquin, D. Safronetz)

Main Article


Comparison of in vitro titers after 7 days of suboptimal storage of vesicular stomatitis–based vaccines*

VSVΔG/LASVGPC Stock vaccine 1.29 × 106 83
3× freeze–thaw 7.43 × 105 1.74 100
4°C for 7 d 1.05 × 106 1.23 83
Room temperature for 7 d 2.86 × 105 4.51 83
32°C for 7 d 3.75 × 104 34.40 66

*VSVΔG/EBOVGPC, vesicular stomatitis virus–based Ebola virus vaccine; VSVΔG/LASVGPC, vesicular stomatitis virus–based Lassa virus vaccine.
†Stock vaccine was not subject to any treatments and thus had no -fold change. The fold change for all other treatment groups was calculated on the basis of the original dose of stock vaccine.

Main Article

Page created: July 17, 2019
Page updated: July 17, 2019
Page reviewed: July 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.